Selenium supplementation levels and sources in postlarvae Nile tilapia diet

Fish larviculture exert great influence in the subsequent phases, in which nutrition is a basic prerequisite for success. Therefore, when it is in an intensified production system, it promotes the limitation of some minerals, making it necessary to supplement selenium in diets for post-larvae. The objective of this study was to evaluate selenium levels and sources in post-larvae Nile tilapia diets on muscle performance and histology. A total of 1,260 post-larvae with an initial average weight of 0.010 g were used, distributed in a completely randomized design in a factorial scheme with four supplementation levels (0.6; 0.9; 1.2 and 1.5 mg of Se/Kg) and two sources (sodium selenite and selenium yeast), plus the negative control, with 35 post-larvae Nile tilapia used per experimental unit. The physical-chemical parameters of water quality were within those recommended for tilapia cultivation. Feed consumption (p < 0.05) and hepatosomatic index (p < 0.05) were affected by the source used. Effects of supplemented selenium levels and sources were not observed for the other performance variables. Higher values for final height, final width, specific development rate and protein efficiency rate were found (p < 0.05) when comparing the control diet with diets containing the sodium selenite source. No effects on muscle fiber morphometry were observed (p > 0.05) in the studied variables. It is concluded that 0.6 mg of selenium in the diet, regardless of the source used, met the mineral requirement for post-larvae Nile tilapia.

The Effects of Body Tempering on Force Production, Flexibility and Muscle Soreness in Collegiate Football Athletes

There has been limited research to explore the use of body tempering and when the use of this modality would be most appropriate. This study aimed to determine if a body tempering intervention would be appropriate pre-exercise by examining its effects on perceived soreness, range of motion (ROM), and force production compared to an intervention of traditional stretching. The subjects for this study were ten Division 1 (D1) football linemen from Sacred Heart University (Age: 19.9 ± 1.5 years, body mass: 130.9 ± 12.0 kg, height: 188.4 ± 5.1 cm, training age: 8.0 ± 3.5 years). Subjects participated in three sessions with the first session being baseline testing. The second and third sessions involved the participants being randomized to receive either the body tempering or stretching intervention for the second session and then receiving the other intervention the final week. Soreness using a visual analog scale (VAS), ROM, counter movement jump (CMJ) peak force and jump height, static jump (SJ) peak force and jump height, and isometric mid-thigh pull max force production were assessed. The results of the study concluded that body tempering does not have a negative effect on muscle performance but did practically reduce perceived muscle soreness. Since body tempering is effective at reducing soreness in athletes, it can be recommended for athletes as part of their pre-exercise warmup without negatively effecting isometric or dynamic force production.

A novel zebrafish model of SPEG-related centronuclear myopathy (CNM): characterization and comparison with other CNM model zebrafish

Centronuclear myopathy (CNM) is a congenital neuromuscular disorder caused by pathogenic variation in genes associated with membrane trafficking and excitation-contraction coupling (ECC). Bi-allelic autosomal recessive mutations in striated muscle enriched protein kinase (SPEG) account for a subset of CNM patients. Previous research has been limited by the perinatal lethality of Speg knockout mice. Thus, the precise biological role of SPEG in skeletal muscle remains unknown. To address this issue, we generated zebrafish spega, spegb, and spega/spegb (speg-DKO) mutant lines. We demonstrate that speg-DKO zebrafish faithfully recapitulate multiple phenotypes associated with human CNM, including disruption of the ECC protein machinery, dysregulation of calcium homeostasis during ECC, and impairment of muscle performance. Taking advantage of the availability of zebrafish models of multiple CNM genetic subtypes, we compared novel and known disease markers in speg-DKO with mtm1-KO and DNM2-S619L transgenic zebrafish. We observed desmin (DES) accumulation common to all CNM subtypes, and Dnm2 upregulation in muscle of both speg-DKO and mtm1-KO zebrafish. In all, we establish a new model of SPEG-related CNM, and identify abnormalities in this model suitable for defining disease pathomechanisms and evaluating potential therapies.

Physical Exercise and Falling among Older Patients with Diabetes: A Narrative Review

Both diabetes mellitus (DM) and aging have an effect on gait behavior, balance, muscle performance, and other medical complications related to the development of diabetic neuropathy, hypoglycemia, hypotension, cognitive impairment, pain, disturbed proprioceptions, and polypharmacy. The main goal of the present review study was to identify risk variables for hypoglycemia-influenced falling in DM older people, to suggest protective interventions to reduce the occurrence and to explore the effect of physical exercise on falling among elderly individuals with DM. In July 2021, these keywords were used to search Google Scholar, PubMed, Embase: falling in elderly, DM complications, insulin, hypoglycemia, and physical exercise. Because falls are so common during activities, it is critical to figure out what elements influence balance and walking activity. Multi-medications, cognitive dysfunction, dementia, urinary incontinence, depression status, and hypoglycemia are just some of the issues that can affect the elements of controlling balance directly during motion. Others, such as multi-medications, cognitive dysfunction, dementia, urinary incontinence, depression status, and hypoglycemia, can affect balance control indirectly by disrupting posture mobility. Exercise training has been shown to increase body performance and reduce joint discomfort, as well as improve psychological status and quality of life, muscular strength and balance, lower the chance of falling, and improve overall health in the aged and older adults.

Urolithin A enhances muscle performance in elderly and positively impacts biomarkers linked to cellular health

Background Aging is associated with decline in mitochondrial function and reduced exercise capacity. Urolithin A (UA) is a natural gut metabolite shown to stimulate mitophagy and improve muscle function in aged animals, and induce mitochondrial gene expression in elderly. Purpose Investigate if oral administration of UA improved walking distance (6MWT), muscle fatigue resistance in hand (FDI) and leg (TA) muscles, and had an impact on plasma biomarkers. Method: We conducted a randomized, double-blind, placebo-controlled study (NCT03283462) in elderly subjects (65-90 yrs.) supplemented daily with 1000mg UA or placebo for 4 months. 128 subjects were screened and 66 randomized. 6MWT and ATPmax via MRS were assessed at baseline and at 4 months. Muscle fatigue tests and plasma analysis of biomarkers were assessed at baseline, 2 and 4 months. Results UA significantly improved muscle endurance (i.e., change in number of muscle contractions from baseline) in two different muscles (hand: PL 11.6 ±147.5, UA 95.3 ± 115.5; and leg: PL 5.7± 127.1, UA 41.4 ±65.5) compared with placebo at 2-months. Plasma levels of several acylcarnitines, ceramides and C-reactive-protein were decreased by UA at the end-of study. 6MWT distance (PL 42.5 ± 73.3 m, UA 60.8± 67.2 m) and ATPmax increased in both groups from baseline (PL 13.7±31.4%, UA19.4± 56.8%) with UA supplemented group exhibiting greater improvements, although these were not statistically different between groups. Conclusion UA supplementation improved muscle endurance, metabolic and inflammatory plasma biomarkers after 2-months, suggesting that UA can have a positive impact on muscle and cellular health in the elderly.

The Severity of Muscle Performance Deterioration in Sarcopenia Correlates With Circulating Muscle Tissue-Specific miRNAs

Sarcopenia is defined as an age-associated loss of skeletal muscle function and muscle mass and is common in older adults. Sarcopenia as a disease is currently of interest not only to orthopedists and surgeons but also to internists, endocrinologists, rheumatologists, cardiologists, diabetologists, gynaecologists, geriatricians and paediatricians. In cooperation with the 5th Internal Medicine Clinic, we, as a unit of clinical research, aimed to describe a sarcopenic specific miRNA expression profile for disease diagnostics and classification of the severity of muscle performance deterioration. This study included a total of 80 patients (age 55-86 years) hospitalized at the V. Internal medicine clinic of LFUK and UNB with different severity of muscle performance deterioration. The study participants were evaluated and classified according to short physical performance battery score (SPPB). In this study, we investigated the role of circulating miRNAs in sarcopenia in the elderly. We hypothesized that sarcopenia effects the expression of muscle tissue-specific miRNAs (MyomiRNAs), which could be potentially reflected in the blood plasma miRNA expression profile. The expression of specific circulating miRNAs in patients with different muscle performances was analyzed. Patients’ blood plasma was evaluated for the expression of myomiRNAs: miRNA-29a, miRNA-29b, miRNA-1, miRNA-133a, miRNA-133b, miRNA-206, miRNA-208b and miRNA-499, and the data were correlated with diagnostic indicators of the disease. We showed a specific sarcopenia miRNA profile that could be considered a possible biomarker for the disease. Patients with low muscle performance showed increased miRNA-1, miRNA-29a and miRNA-29b expression and decreased for the miRNA-206, miRNA-133a, miRNA-133b, miRNA-208b and miRNA-499 expression. We show that the severity of muscle performance deterioration in sarcopenia correlates with specific miRNA expression. We also propose the profile of miRNAs expression in blood plasma as a specific biomarker for sarcopenia diagnostics. Future clinical studies will be necessary to eventually naturally have to elucidate the underlined molecular mechanism responsible for specific miRNAs expression in sarcopenia pathology and progression of the disease.